160 completed, 19 terminated, 13 recruiting, 11 unknown. 213 Phase 1, 29 Phase 2.
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation Apremilast XR, Apremilast IR - Psoriasis, Arthritis, Psoriatic | Phase 1 | Not yet recruiting | Amgen | 114 | 2026-11-18 | 2026-11-02 |
| A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001) MK-8644, Placebo for MK-8644 - Psoriasis, Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 132 | 2026-10-20 | 2026-10-27 |
| A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults HCXT-2001 Tablets, Placebo, HCXT-2001 Tablets(A) - Psoriasis | Phase 1 | Not yet recruiting | Shanghai Peptidstar Therapeutics Limited | 40 | 2026-10-14 | 2026-10-13 |
| A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants DRL_AB - Healthy Volunteers | Phase 1 | Not yet recruiting | Dr. Reddy's Laboratories Limited | 160 | 2026-08-19 | 2026-08-04 |
| A Study of HL40626S Tablets in Healthy Adults HL40626S tablets, HL40626S placebo - Skin Disease, Immune System Disease | Phase 1 | Recruiting | HighsLab Therapeutics Inc. | 64 | 2026-08-05 | 2026-10-29 |
| Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease S-4321 - Autoimmune Diseases, Rheumatoid Arthritis (RA) | Phase 1 | Recruiting | Seismic Therapeutic AU Pty Ltd | 24 | 2026-06-01 | 2026-06-01 |
| Trial of HSK44459 Cream for the Management Plaque Psoriasis HSK44459 Cream, Vehicle - Psoriasis | Phase 1 / Phase 2 | Active not recruiting | Haisco Pharmaceutical Group Co., Ltd. | 180 | 2026-05-22 | 2026-06-08 |
| Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis ARQ-154 Foam 0.3% - Psoriasis | Phase 1 | Completed | Arcutis Biotherapeutics, Inc. | 22 | 2025-12-15 | 2026-05-22 |
| Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers Secukinumab 150mg s.c. - Psoriasis | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 114 | 2025-12-15 | 2026-10-21 |
| A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc - Psoriatic Arthritis, Axial Spondyloarthritis | Phase 1 | Recruiting | UCB Biopharma SRL | 392 | 2025-12-10 | 2026-07-06 |
| Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants SKYRIZI, CKD-704 - Psoriasis | Phase 1 | Recruiting | Chong Kun Dang Pharmaceutical | 213 | 2025-11-26 | 2025-12-19 |
| A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections ABBV-547, ABBV-547 Placebo - Healthy Volunteer, Psoriasis | Phase 1 | Active not recruiting | AbbVie | 142 | 2025-11-24 | 2026-10-15 |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) Bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 1 | Recruiting | UCB Biopharma SRL | 20 | 2025-11-05 | 2026-09-18 |
| A Trial of SHR-1139 in Healthy Volunteers SHR-1139 Injection - Psoriasis | Phase 1 | Active not recruiting | Atridia Pty Ltd. | 24 | 2025-08-19 | 2026-03-19 |
| Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis LPX-TI641, Placebo - Atopic Dermatitis (AD), Psoriasis (PsO) | Phase 1 | Recruiting | LAPIX Therapeutics Inc. | 48 | 2025-06-15 | 2025-12-19 |
| A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) HS-10374 tablets, Drospirenone and Ethinyl Estradiol tablets - Psoriasis (PsO) | Phase 1 | Completed | Hansoh BioMedical R&D Company | 18 | 2025-05-28 | 2025-09-18 |
| Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118 HS-20118 - Psoriasis | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 142 | 2025-05-16 | 2025-06-24 |
| Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118 HS-20118, HS-20118 placebo - Psoriasis | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 132 | 2025-05-02 | 2025-08-07 |
| Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis. Ustekinumab - Psoriasis, Crohn Disease | Phase 1 | Recruiting | University Medical Center Groningen | 56 | 2025-01-06 | 2025-01-15 |
| Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone Cyclosporin (CSA), Metformin (500 mg Twice a day) - Psoriasis | Phase 1 | Completed | Cairo University | 32 | 2024-12-19 | 2026-01-29 |
Showing 20 of 213. Sign in to see all of them.
Arthritis, Psoriatic (31) · Arthritis, Rheumatoid (16) · Dermatitis, Atopic (9) · Autoimmune Diseases (8) · Crohn Disease (8) · Spondylitis, Ankylosing (6) · Axial Spondyloarthritis (5) · Colitis, Ulcerative (5) · Arthritis (4) · Arthritis, Juvenile (4) · Hidradenitis Suppurativa (4) · Inflammatory Bowel Diseases (4) · Lupus Erythematosus, Systemic (4) · Skin Diseases (4)
Skin and Connective Tissue Diseases (213) · Skin Diseases, Papulosquamous (212) · Skin Diseases (209) · Musculoskeletal Diseases (38) · Joint Diseases (37) · Arthritis (34) · Immune System Diseases (33) · Bone Diseases (32) · Spinal Diseases (32) · Spondylarthritis (32) · Spondylarthropathies (32) · Spondylitis (32) · Connective Tissue Diseases (19) · Rheumatic Diseases (16)
calcipotriene (11) · Hemay005 (8) · Ustekinumab (7) · secukinumab (7) · Methotrexate (6) · Midazolam (6) · deucravacitinib (6) · Betamethasone (4) · Cyclosporine (4) · guselkumab (4) · risankizumab (4) · Adalimumab (3) · Caffeine (3) · Clobetasol (3) · Ointments (3)
Bristol-Myers Squibb (8) · Eli Lilly and Company (8) · GlaxoSmithKline (8) · Pfizer (6) · AbbVie (5) · Bausch Health Americas, Inc. (4) · Bayer (4) · Bio-Thera Solutions (4) · Boehringer Ingelheim (4) · Ganzhou Hemay Pharmaceutical Co., Ltd (4) · Guangdong Provincial Hospital of Traditional Chinese Medicine (4) · Novartis Pharmaceuticals (4) · Amgen (3) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (3) · Evelo Biosciences, Inc. (3)
United States (79) · China (35) · Germany (28) · Australia (17) · Canada (14) · United Kingdom (14) · New Zealand (11) · Netherlands (6) · Japan (5) · Austria (4) · Bulgaria (4) · France (4) · Moldova (4) · Poland (4) · Switzerland (4)
Chuanjian Lu, PhD (2) · Duncan McHale, MD, PhD (2) · Hongyun Wang, Doctor (2)
PMID 41545329, PMID 18645136, PMID 19587341, PMID 20231202, PMID 20811392, PMID 22622425, PMID 22653877, PMID 23607128, PMID 25749867, PMID 26252485, PMID 27859546, PMID 28814432, PMID 29030361, PMID 29150844, PMID 29275332, PMID 30100374, PMID 30574672, PMID 30937241, PMID 31054118, PMID 32407591, PMID 32767679, PMID 32845114, PMID 33241960, PMID 34988162, PMID 35262901, PMID 35470301, PMID 36417156, PMID 36422852, PMID 36566344, PMID 36919398, PMID 37184136, PMID 37212315, PMID 37215725, PMID 37300792, PMID 37356077, PMID 37483071, PMID 38231873, PMID 38580386, PMID 39104539, PMID 39224901, PMID 39455575, PMID 40520205, PMID 41452420, PMID 42012633
2017 (6), 2016 (4), 2018 (3), 2014 (2), 2015 (2), 2019 (2), 2025 (2), 2009 (1), 2023 (1), UM1CA186688 (1)